search
Back to results

Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes

Primary Purpose

Overactive Bladder Syndrome

Status
Completed
Phase
Phase 4
Locations
Taiwan
Study Type
Interventional
Intervention
solifenacin
mirabegron
Sponsored by
National Taiwan University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Overactive Bladder Syndrome

Eligibility Criteria

20 Years - 99 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Women with overactive bladder syndrome
  • ≥20 year-old

Exclusion Criteria:

  • Urine retention,
  • acute angle glaucoma,
  • myasthenia gravis,
  • ulcerative colitis,
  • megacolon

Sites / Locations

  • Outpatient clinics, Department of Obs/Gyn, National Taiwan University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

Solifenacin

Mirabegron

Arm Description

Women with overactive bladder syndrome will be treated by solifenacin 5 mg qd * 12 weeks

Women with overactive bladder syndrome will be treated by mirabegron 25 mg qd * 12 weeks

Outcomes

Primary Outcome Measures

Between-group difference of the effect of drug on heart rate variability
Between-group difference of the effect of drug on heart rate variability, such as low frequency and high frequency
Between-group difference of the effect of drug on psychosomatic distress
Between-group difference of the effect of drug on psychosomatic distress by Brief Symptom Rating Scale

Secondary Outcome Measures

Between-group difference of the effect of drug on arterial stiffness
Between-group difference of the effect of drug on arterial stiffness by cardio-ankle vascular index
Between-group difference of the effect of drug on clinical efficacy
Between-group difference of the effect of drug on clinical efficacy by Overactive Bladder Symptoms Score Questionnaire

Full Information

First Posted
August 27, 2015
Last Updated
March 27, 2023
Sponsor
National Taiwan University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT02540707
Brief Title
Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes
Official Title
Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes: A Prospective Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Completed
Study Start Date
September 8, 2015 (Actual)
Primary Completion Date
August 26, 2020 (Actual)
Study Completion Date
August 26, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Taiwan University Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Background/Purpose: The overactive bladder syndrome (OAB) affects around 17 % of female population. Antimuscarinics can affect autonomic system, arterial stiffness and psychosomatic distress. However, there is no such research for the new drug- mirabegron (a β3-agonist). Thus, the aim of our study is to analyze the between-group differences in heart rate variability, cardio-ankle vascular index, ankle-brachial pressure index, psychosomatic distress, personality trait, family support and clinical outcomes between the mirabegron and the solifenacin groups. Patients and Methods: The investigators will perform a prospective randomized controlled study to recruit 150 female OAB patients at the outpatient clinic of Department of Obstetrics and Gynecology of National Taiwan University Hospital. All OAB female patients will be asked to complete Urgency Severity Scales, Overactive Bladder Symptoms Scores questionnaires, King's Health questionnaires, UDI-6 & IIQ-7, Patient Health Questionnaire, brief symptom rating scale (BSRS), Maudsley personality inventory (MPI) and adaptability, partnership, growth, affection, and resolve (APGAR) questionnaires, Sleep and Dietary habit Questionnaire, standard 12-leads electrocardiography (ECG), 5 minutes Holter monitoring, cardio-ankle vascular index (CAVI) test, bladder diary, 20-min pad test, urodynamic studies and measurement of urinary nerve growth factors level before and after 12 weeks' mirabegron versus solifenacin treatment. STATA software is used for statistical analyses. Possible Results: The investigators can answer that the between-group differences in heart rate variability, cardio-ankle vascular index, ankle-brachial pressure index, psychosomatic distress, personality trait, family support and clinical outcomes between the mirabegron and the solifenacin groups. The above conclusions should be important for pre-treatment consultation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overactive Bladder Syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
113 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Solifenacin
Arm Type
Placebo Comparator
Arm Description
Women with overactive bladder syndrome will be treated by solifenacin 5 mg qd * 12 weeks
Arm Title
Mirabegron
Arm Type
Experimental
Arm Description
Women with overactive bladder syndrome will be treated by mirabegron 25 mg qd * 12 weeks
Intervention Type
Drug
Intervention Name(s)
solifenacin
Intervention Description
solifenacin 5 mg per day for 12 weeks
Intervention Type
Drug
Intervention Name(s)
mirabegron
Intervention Description
mirabegron 25 mg per day for 12 weeks
Primary Outcome Measure Information:
Title
Between-group difference of the effect of drug on heart rate variability
Description
Between-group difference of the effect of drug on heart rate variability, such as low frequency and high frequency
Time Frame
12 weeks
Title
Between-group difference of the effect of drug on psychosomatic distress
Description
Between-group difference of the effect of drug on psychosomatic distress by Brief Symptom Rating Scale
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Between-group difference of the effect of drug on arterial stiffness
Description
Between-group difference of the effect of drug on arterial stiffness by cardio-ankle vascular index
Time Frame
12 weeks
Title
Between-group difference of the effect of drug on clinical efficacy
Description
Between-group difference of the effect of drug on clinical efficacy by Overactive Bladder Symptoms Score Questionnaire
Time Frame
12 weeks

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Women with overactive bladder syndrome ≥20 year-old Exclusion Criteria: Urine retention, acute angle glaucoma, myasthenia gravis, ulcerative colitis, megacolon
Facility Information:
Facility Name
Outpatient clinics, Department of Obs/Gyn, National Taiwan University Hospital
City
Taipei
ZIP/Postal Code
100
Country
Taiwan

12. IPD Sharing Statement

Learn more about this trial

Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes

We'll reach out to this number within 24 hrs